Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Yonaton Ray

Andrew J Murphy

Jesper Gromada

Jee Hwan Kim

Panayiotis Stevis

Ivan Borisovich Lobov

Ivan B Lobov

Jee H Kim

The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

Fusion protein comprising apelin and an anti-APLNR antibody

The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, that inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.

Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR

Methods for improving cardiac function by administering an antibody that activates APLNR

APLNR modulators and uses thereof

Antibody modulators of APLNR

Growing community of inventors

Bergenfield, NJ, United States of America

Yonaton Ray